Hi-Tech Pharmacal (HITK) Tops Q2 Earnings Views
More News related to HITK
- Hi-Tech Pharmacal to Present at the 20th Annual Oppenheimer Healthcare Conference
- FTN Equity Downgrades Hi-Tech Pharmacal (HITK) from Buy
- Unusual 11 Mid-Day Movers 9/9: ENCO, VVUS, CLZR, HITK, DPTR Higher; OPXA, LRN, ROSG, ELOS Lower
- Morning Movers 9/9: ENCO, VVUS, CLZR, WAVX, HITK, ISTA Higher; HNAB, ENWV, UWBK, AVAV, PBY Lower
- Hi-Tech Pharmacal (HITK) Reports Surge in Q1 Sales and EPS
More News related to Earnings
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) reports Q2 EPS of $0.09, 3 cents better than the analyst estimate of $0.06. Revenue for the quarter was $25.1 million, versus the consensus of $22.50 million. (only 1 analyst covers the stock)
Hi-Tech Pharmacal Co., Inc. develops, manufactures, markets, and sells generic, prescription, over-the-counter (OTC), and nutritional products in liquid and semisolid dosage forms in the United States.
Related Categories
EarningsStocks Mentioned
-0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
